Novelix Pharmaceuticals Ltd

📈 Novelix Pharma Expands Capital Base with Warrant Conversion

• Allotted 1,150,000 equity shares at ₹20 each (₹10 face value + ₹10 premium)

• Total conversion amount: ₹1,72,50,000

• Major allottees: SRINIDHI FINE-CHEMICALS LLP (1,100,000 shares) and NARAHARI BELIDE (50,000 shares)

• Paid-up equity capital increased from ₹1,99,35,000 (1,993,500 shares) to ₹2,10,85,000 (2,108,500 shares)

• Mr. Jivamohan Divakar Valluri resigns as Non-Executive Director effective March 30, 2026 due to personal commitments